PACB

Pacific Biosciences of California

PACB, USA

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, Sequel, Sequel II, and Sequel IIe instruments which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. It serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

https://www.pacb.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PACB
stock
PACB

Barclays Maintains Rating and Increases Price Target for PACB | PACB Stock News GuruFocus

Read more →
PACB
stock
PACB

Barclays Issues Positive Forecast for Pacific Biosciences of California (NASDAQ:PACB) Stock Price MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$2.2857

Analyst Picks

Strong Buy

5

Buy

1

Hold

8

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

17.67

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-105.29 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-4.73 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-48.89 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

21.25

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 95.55% of the total shares of Pacific Biosciences of California

1.

ARK Investment Management LLC

(12.0845%)

since

2025/06/30

2.

BlackRock Inc

(7.5416%)

since

2025/06/30

3.

ARK Disruptive Innovation Full Composite

(7.2685%)

since

2025/06/30

4.

SoftBank Group Corp

(6.8088%)

since

2025/06/30

5.

Madrone Advisors LLC

(5.5805%)

since

2025/06/30

6.

ARK Innovation ETF

(5.4078%)

since

2025/08/28

7.

Vanguard Group Inc

(5.3325%)

since

2025/06/30

8.

Edmond de Rothschild Holding S.A.

(4.4499%)

since

2025/06/30

9.

EdRF Big Data N EUR

(4.0156%)

since

2025/07/31

10.

ARK Genomic Revolution

(3.6591%)

since

2025/06/30

11.

ARK Genomic Revolution ETF

(3.6288%)

since

2025/08/28

12.

Amova Asset Management Americas, Inc

(3.069%)

since

2025/06/30

13.

Sumitomo Mitsui Trust Group Inc

(3.069%)

since

2025/06/30

14.

Vanguard Total Stock Mkt Idx Inv

(2.9286%)

since

2025/07/31

15.

iShares Russell 2000 ETF

(2.254%)

since

2025/08/31

16.

Geode Capital Management, LLC

(2.2369%)

since

2025/06/30

17.

State Street Corp

(1.9158%)

since

2025/06/30

18.

Amova ARK Pstv Chg Innovt P JPY Acc

(1.5845%)

since

2025/07/31

19.

Amova ARK Disruptive Innovation A USD

(1.1896%)

since

2025/07/31

20.

Koss-Olinger Consulting, LLC

(1.0986%)

since

2025/06/30

21.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9883%)

since

2025/07/31

22.

Fidelity Small Cap Index

(0.9219%)

since

2025/06/30

23.

Point72 (DIFC) Ltd

(0.8187%)

since

2025/06/30

24.

iShares Russell 2000 Value ETF

(0.7979%)

since

2025/08/31

25.

Charles Schwab Investment Management Inc

(0.7624%)

since

2025/06/30

26.

Northern Trust Corp

(0.7345%)

since

2025/06/30

27.

UBS Group AG

(0.6636%)

since

2025/06/30

28.

iShares Biotechnology ETF

(0.5313%)

since

2025/08/31

29.

Fidelity Extended Market Index

(0.505%)

since

2025/07/31

30.

Vanguard Russell 2000 ETF

(0.4381%)

since

2025/07/31

31.

Schwab US Small-Cap ETFâ„¢

(0.4367%)

since

2025/08/30

32.

Vestmark Advisory Solutions, Inc

(0.4309%)

since

2025/06/30

33.

Susquehanna International Group, LLP

(0.427%)

since

2025/06/30

34.

Bourne Stenstrom Capital Management Inc

(0.3237%)

since

2025/06/30

35.

XTX Topco Ltd

(0.3178%)

since

2025/06/30

36.

State St Russell Sm Cap® Indx SL Cl I

(0.3099%)

since

2025/08/31

37.

Hillhouse Capital Advisors, Ltd.

(0.3059%)

since

2025/06/30

38.

Vanguard Health Care ETF

(0.2539%)

since

2025/07/31

39.

Schwab Small Cap Index

(0.2368%)

since

2025/07/31

40.

NT R2000 Index Fund - NL

(0.2252%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.12

EPS Estimate

-0.14

EPS Difference

0.02

Surprise Percent

14.2857%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(1.5)
Defensive
Moderately Defensive(5)
Dividend
Weak Dividend Profile(1)
Economic Moat
Some Competitive Advantage(3.3)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(1)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(1)
Value
Overpriced(1.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.